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Abstract: The high morbidity, mortality, and health care costs associated with invasive fungal 
infections, especially in the critical care setting and immunocompromised host, have made it 
an excellent target for prophylactic, empiric, and preemptive therapy interventions principally 
based on early identiﬁ  cation of risk factors. Early diagnosis and treatment are associated with 
a better prognosis. In the last years there have been important developments in antifungal phar-
macotherapy. An approach to the new diagnosis tools in the clinical mycology laboratory and 
an analysis of the use new antifungal agents and its application in different clinical situations 
has been made. Furthermore, an attempt of developing a state of the art in each clinical scenario 
(critically ill, hematological, and solid organ transplant patients) has been performed, trying 
to choose the best strategy for each clinical situation (prophylaxis, pre-emptive, empirical, or 
targeted therapy). The high mortality rates in these settings make mandatory the application of 
early de-escalation therapy in critically ill patients with fungal infection. In addition, the pos-
sibility of antifungal combination therapy might be considered in solid organ transplant and 
hematological patients.
Keywords: invasive fungal infections, prophylaxis, empirical therapy, preemptive treatment, 
targeted therapy
Introduction
Hospital medicine has advanced greatly in the past few decades. Patients with complex 
medical and surgical disorders are surviving longer due to equally complex medical 
and surgical interventions, which often involve “collateral damage” by avoiding normal 
body defensive mechanisms.
Invasive fungal infections (IFIs) in adult patients, especially in the critical care 
setting, solid organ transplant (SOT), and hematological patients, have become an 
excellent target for prophylactic, empiric, and pre-emptive therapy interventions due to 
their increasing incidence, high morbidity and mortality rates, and associated health care 
costs. Early diagnosis and treatment are associated with a better prognosis. Although 
at present, the number of systemic antifungal agents has increased signiﬁ  cantly, the 
choice of antifungal drug must be based on the individual characteristics of the patient, 
clinical scenario, and the presence of hemodynamic instability. A tailored therapy 
(de-escalation) must also be considered in some clinical situations.
Different possible strategies based on diagnoses stage has been described as pro-
phylactic, empiric, pre-emptive and targeted antifungal therapy (Figure 1). Prophylactic 
treatment refers to the preventive administration of an antifungal agent to patients 
at risk of IFI without attributable signs and symptoms. Empiric treatment is deﬁ  ned Therapeutics and Clinical Risk Management 2008:4(6) 1262
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as the initiation of antifungal treatment in patients at high 
risk of IFIs and established clinical signs and symptoms, 
but without microbiological documentation, whereas pre-
emptive therapy is applied when the decision of treatment 
is based on early diagnostic test. Finally, targeted therapy 
needs a pathogen identiﬁ  cation to be deﬁ  ned.
The aim of this multidisciplinary review was to analyze 
the best option for treating this special population of adults 
patients, describing the antifungal armamentarium, making 
an approach to the mycology laboratory diagnosis and ﬁ  nally 
developing a state of the art clinical scenario (critically ill, 
hematological and transplant patients) trying to choose 
the best strategy for each clinical situation (prophylaxis, 
empirical, pre-emptive, or targeted therapy).
Role of the mycology laboratory 
in the antifungal therapy options
Microbiological diagnosis for preventive 
treatment
The incidence of IFIs has steadily increased in the past two 
decades. These infections represent an additional difﬁ  culty in 
the management of immunocompromised patients and are a 
contributory cause of death in allogeneic hematopoietic stem 
cell and SOT recipients and in patients undergoing intensive 
chemotherapy (Cordonnier et al 2006).
The high mortality associated with IFIs is partly cor-
related to the difﬁ  culties of making an early diagnosis due 
to the nonspeciﬁ  c clinical features and the low sensitivity 
of microscopy, histological examination, conventional 
radiology and cultures of specimens obtained from at-risk 
patients (Hope et al 2005). However, improved survival 
can be obtained by earlier initiation of antifungal therapy. 
The time period between the biological onset of a fungal 
infection and the appearance of clinical signs and symptoms 
represents a window of opportunity that, if identiﬁ  ed through 
prospective screening, may allow for pre-emptive therapeutic 
intervention. In this diagnostic area, progress could come 
from prospective screening strategies using new serodiag-
nostic assays (galactomannan and (1-3)-β-D-glucan) and/or 
polymerase chain reaction (PCR) techniques for the detection 
of fungal-speciﬁ  c DNA.
Thus, to improve earlier diagnosis and survival of IFIs, 
new nonculture-based microbiological tools should be used 
in conjunction with modern imaging techniques in addition to 
conventional microbiological, histological, and radiological 
procedures.
Nonculture-based microbiological tools
With the aim of improving the rapid and early diagnosis of 
IFIs, new microbiological nonculture-based assays have been 
developed in the last years, including detection of fungal 
galactomannan, (1-3)-β-D-glucan antigen, Candida albicans 
germ tube antibodies and fungal DNA.
Galactomannan detection
Galactomannan (GM) is a polysaccharide cell wall 
component released by the Aspergillus species dur-
ing hyphal growth. The detection of galactomannan by 
sandwich-enzyme immunoassay (EIA), Platelia Aspergillus 
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Figure 1 Different antifungal strategies for treatment in invasive fungal infections based on diagnostic stage.Therapeutics and Clinical Risk Management 2008:4(6) 1263
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(Bio-Rad Laboratories, Marnes-La-Coquette, France), 
has been approved in Europe and the USA for use in 
hematopoietic stem cell transplant (HSCT) recipients. 
Furthermore, its detection in body ﬂ  uids (mainly serum 
and bronchoalveolar lavage) was included in the 2002 
EORTC-MSG consensus deﬁ  nitions of invasive aspergil-
losis (IA) as a microbiological criterion having the same 
weight as the isolation of Aspergillus spp. or the micro-
scopic demonstration of hyphae from a nonsterile body 
site (Ascioglu et al 2002).
Using EIA, circulating galactomannan may be detected 
at a median of 5–8 days (range 1–27 days) before clinical 
signs and symptoms of IA become evident. Furthermore, 
the concentration of circulating galactomannan corresponds 
with the fungal tissue burden and may therefore be used 
to monitor the patient’s response to antifungal treatment 
(Maertens et al 2001).
The results of the unique meta-analysis published of 
the diagnostic value of GM detection with the Platelia 
Aspergillus® assay have shown that for proven and probable 
cases of IA, the pooled (adults and pediatrics) sensitivity was 
only 61% whereas the overall speciﬁ  city was 93%. In general, 
the negative predictive value and the speciﬁ  city are excel-
lent (95%), suggesting that the assay can be used to rule 
out the diagnosis of IA (Pfeiffer et al 2006). False-positive 
results have been reported in adults (5.7%–14%), but among 
pediatric patients and neonates these are notably higher (83%) 
(Sulahian et al 2003). Reasons for false reactivity remain 
largely unknown, although piperacillin – tazobactam could be 
a cause of cross-reactivity in adults (Sulahian et al 2003), and 
cross-reacting epitopes from Biﬁ  dobacterium spp. were pro-
posed as a cause in neonates (Mennink-Kersten et al 2004). 
In summary, the GM assay has moderate accuracy for the 
diagnosis of IA in immunocompromised patients. The test is 
more useful in patients who have hematological malignancies 
or who have undergone hematopoietic cell transplantation 
than in solid-organ transplant recipients. Nevertheless, some 
important issues in relation to the performance of this assay 
still remain unanswered, such as the impact of antifungal 
prophylaxis, the inﬂ  uence of therapy with fungal cell wall 
inhibitors, or the handling of false-positive and false-negative 
values (Maertens et al 2006).
Recenty, a very interesting study has evaluated GM 
detection in BAL ﬂ  uid in critically ill patients with signs 
of pneumonia. Patients were classiﬁ  ed as having proven, 
probable, or possible IA. Using a cutoff index of 0.5, the 
sensitivity and speciﬁ  city of GM detection in BAL ﬂ  uid 
was 88% and 87%, respectively. The sensitivity of serum 
GM was only 42%. In 11 of 26 proven cases of IA, BAL 
culture and serum GM remained negative, whereas GM in 
BAL was positive. Following these rresults GM detection in 
BAL ﬂ  uid could be useful in establishing or excluding the 
diagnosis of IA in intensive care units (ICU) (Meersseman 
et al 2008).
Detection of (1,3)-β-D-glucan
Glucans are a cell wall component of most pathogenic fungi 
except Zygomycetes and Cryptococcus spp. (1-3)-β-D-glucan 
can be detected in serum in amounts as low as 1 pg/ml by 
commercial assays. One of them, Fungitell (Associates of 
Cape Cod Inc., East Falmout, MA), has been approved by 
the FDA as an adjunct for the diagnosis of IFIs in the USA, 
based on its evaluation in hematological patients (Odabasi 
et al 2004). At a cut-off of 60 pg/ml, the negative predictive 
value of twice-weekly sampling was 100%, and sensitivity 
was 100% if one positive assay was considered a positive 
result. Furthermore, the results were not inﬂ  uenced by the 
use of prophylactic or empirical antifungals. (1,3)-β-D-glucan 
is a broad spectrum fungal marker and can detect invasive 
infections due to Aspergillus, Candida, Fusarium, Acremo-
nium, Scedosporium, Pneumocystis jiroveci, etc., but, after a 
positive result, the invasive infection must be assessed using 
radiological and microbiological techniques. To date, overall 
experience with this test remains limited; furthermore, its 
methodological concerns (use of endotoxin-free and glucan-
free glassware) and false-positive results (due to albumin, 
immunoglobulins, glucan-containing gauze, hemodialysis or 
Gram-positive bacteremia) make its use difﬁ  cult in a clinical 
setting. However, based on the excellent negative predictive 
value, detection of (1-3)-β-D-glucan seems to be most useful 
for excluding IFIs (Pickering et al 2005).
Multicenter clinical trial results have demonstrated that 
(1,3)-β-D-glucan assay can be used in clinical specimens with 
a high speciﬁ  city and positive predictive value for subjects 
with proven or probable IFI when compared with control 
subjects (Ostrosky-Zeichner et al 2005). This test appears 
to be useful both as a single-point assay for hospitalized 
patients with a possible fungal infection and as part of a 
surveillance strategy in high-risk patients. A cut-off value of 
60 or 80 pg/mL appears to be optimal for this test. At a cutoff 
of 60 pg/mL, the sensitivity and speciﬁ  city of the assay were 
69.9% and 87.1%, respectively, with a positive predictive 
value (PPV) of 83.8% and a negative predictive value (NPV) 
of 75.1%. At a cutoff value of 80 pg/mL, the sensitivity and 
speciﬁ  city were 64.4% and 92.4%, respectively, with a PPV 
of 89% and an NPV of 73%.Therapeutics and Clinical Risk Management 2008:4(6) 1264
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Detection of fungal DNA
In recent years novel molecular methods, notably the 
ampliﬁ  cation of gene sequences unique to fungi by polymerase 
chain reaction (PCR) assays, have been developed to improve 
the diagnosis of life-threatening IFIs in high-risk patients. PCR 
offers the potential for rapid diagnosis. However, due to the 
absence of a standardized and validated commercial method, 
the routine use of PCR in the diagnosis of IFI cannot yet be 
recommended. Real-time techniques combined with auto-
mated DNA extraction may, however, allow standardization 
and reproducibility between centers, and may broaden the 
clinical applicability of PCR-based diagnosis in the near future 
(Maertens et al 2006).
Antibodies against Candida albicans germ tubes
A C. albicans mannoprotein located on the germ tube cell 
wall surface is recognized by sera from patients with invasive 
candidiasis (IC). Recently, an indirect immunoﬂ  uorescence 
assay to detect antibodies (CAGTA) against this antigen 
has been developed and commercialized (C. albicans IFA 
IgG; Vircell Laboratories, Spain) (Moragues et al 2004; 
Ponton et al 1994). The test has shown an overall sensitivity 
of 77%–89% and a speciﬁ  city of 91%–100% and has been 
useful in the diagnosis of IC in intravenous heroin users, bone 
marrow transplant recipients and hematological or intensive 
care patients (Quindos et al 2004). Detection of CAGTA 
in patients with invasive infections caused by Candida 
spp. other than C. albicans (C. tropicalis, C. parapsilosis, 
C. glabrata, C. dubliniensis, C. guilliermondii, and C. krusei) 
may also be positive, although titers are lower than for 
candidiasis caused by C. albicans. In addition, the detection 
of CAGTA may be useful for the therapeutic monitoring 
of patients with IC, since the administration of antifungal 
therapy usually results in decreasing titers of CAGTA 
(Moragues et al 2004).
In 2006, our group evaluated an immunoﬂ  uorescence 
assay for CAGTA detection in a selected population of 
critically ill patients (Zaragoza et al 2006). Although there 
were no differences between CAGTA-positive and -negative 
patients in terms of age, gender, sequential organ failure 
assessment score, and renal and hepatic failure, the intra-ICU 
mortality rate was signiﬁ  cantly lower in patients who tested 
positive for CAGTA (25% vs 65.2%; P = 0.025). These 
results imply that a strategy based on the early determination 
of CAGTA expression might reduce the ICU mortality rate 
of patients with risk factors for the development of IC. 
However, more studies are needed to validate this approach 
in the critical care setting.
Combinations of nonculture-based 
microbiological tools
Recent studies focusing on the combination of 
nonculture-based microbiological tools have demon-
strated improved diagnostic accuracy when combining 
galactomannan and (1-3)-β-D-glucan detection (Pazos et al 
2005), as well as galactomannan and PCR (Millon et al 
2005; Florent et al 2006). Additionally, its usefulness for 
diagnosing and monitoring IC using (1-3)-β-D-glucan and 
CAGTA was evaluated in neutropenic adults at high risk. 
Both tests anticipated the clinical and radiological diagno-
sis, and the initiation of antifungal therapy in most patients. 
A combination of both tests improved speciﬁ  city and positive 
predictive value to 100% (Pazos et al 2006). These studies 
suggest that a combination of two tests to detect antigen, 
antibodies, (1-3)-β-D-glucan and DNA will be needed to 
optimize the diagnosis of systemic fungal infections (Ponton 
and del Palacio 2007).
Culture-based microbiological tools
Diverse risk factors for IC, including prior Candida spp. 
colonization, could allow the detection of patients that may 
be potential candidates for preemptive antifungal therapy. 
Numerous patients are colonized in the ICU but only few 
subsequently develop systemic candidiasis. Screening for 
Candida colonization assessment is performed routinely 
in many ICUs. Nevertheless, the value of positive surveil-
lance cultures and of several developed colonization indexes 
for the prediction of IC and the indication for preemptive 
antifungal therapy is currently under active investigation 
(Piarroux et al 2004). Recently, a simple scoring system 
(“Candida score”) has been evaluated to assist clinicians in 
differentiating between Candida species colonization and 
proven Candida infection in nonneutropenic critically ill 
patients (Leon et al 2006).
In conclusion, although substantial progress has been 
made in the diagnosis of IFIs, no single test has found 
widespread clinical use. There is a consensus in publica-
tions that results obtained from a panel of diagnostic tests in 
association with blood culture ﬁ  ndings and clinical aspects 
of the patient will likely be the most useful strategy for the 
early diagnosis of patients with IFIs and the monitoring of 
therapeutic response.
The laboratory and the empirical 
antifungal therapy
In patients at high risk of fungal infection, the administration 
of empirical antifungal treatment must be considered Therapeutics and Clinical Risk Management 2008:4(6) 1265
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since a relationship between the delay in the initiation of 
treatment and in clinical outcome and hospital mortality 
has been demonstrated (Morrell et al 2005; Garey et al 
2006). Empirical antifungal therapy is defined as the 
treatment administered to patients who have several risk 
factors and clinical features for IFIs, when microbiological 
documentation, species identiﬁ  cation or susceptibility data 
are still not available.
When this treatment is to be established, several factors 
must be taken into account, such as: 1) the hospital area 
epidemiology; 2) previous susceptibility data of species 
isolated in the hospital area; 3) the multicenter surveillance 
studies to predict the susceptibility patterns of isolates; 4) the 
potential risk of emergence of ﬂ  uconazole resistance or 
appearance of candidiasis due to ﬂ  uconazole-resistant species 
among patients receiving ﬂ  uconazole prophylaxis (Agresti 
et al 1994); 5) the presence of neutropenia; 6) the underlying 
patient conditions which can affect the metabolism of the 
drug; 7) the toxicity of the antifungal agent; and 8) previous 
experience in fungal treatment. Furthermore, it must be kept 
in mind that any individual isolate of any species may become 
resistant to any antifungal agent.
Table 1 summarizes the in vitro susceptibility patterns 
of yeasts and moulds against the most frequently isolated 
species. These data are representative of those published in 
numerous in vitro studies.
In summary, as epidemiological data and resistance to 
antifungal agents depends on characteristics of patients and 
geographical localization, it is convenient, in all invasive 
mycoses, to perform both the identiﬁ  cation of all isolates at 
species level and the antifungal susceptibility tests to identify 
the local epidemiology so as to apply the most appropriate 
empirical therapy in each institution.
Prophylaxis, empirical, pre-emptive 
or targeted therapy, which is the 
best in critically ill patients?
Approximately 10.4% of infections in an ICU are related to 
Candida spp. with the majority being nosocomial (Alberti 
et al 2002). However, this rate could be underestimated due 
to the fact that at least 4% of critically ill patients who die in 
an ICU present an unexpected fungal infection during post-
mortem examination (Dimopoulos et al 2004). Furthermore, 
ICU admission itself has become an independent risk factor 
Table 1 Usual susceptibility patterns for yeasts and moulds
Species Amphotericin B Fluconazole Itraconazole Voriconazole Posaconazole Echinocandins
C. albicans Sa SS S S S
C. tropicalis SS S S S S
C. parapsilosis SS S S S S b
C. glabrata S, R SDD, Rc SDD, Rd Sb Sb S
C. krusei S, R R SDD, Rd Sb Sb S
C. lusitaniae S, Re SS S S S
C. guilliermondii S, R S, SDD S S S
C. dubliniensis S, Rb S, SDD, R S S S
Trichosporon spp. S, R S, SDD, R S, SDD S R
Blastoschizomyces S, R S, SDD, R S, SDD S R
Malassezia spp. S, R S S S ND
Rhodotorula spp. S S, SDD S, SDD S, SDD R
Cryptococcus spp. S S, SDD S S S R
A. fumigatus S R S, R S S S
A. terreus RR S S S S
A. niger SR S S S S
A. ﬂ  avus SR S S S S
Fusarium solani RR R S S R
S. apiospermum RR R S S S
S. proliﬁ  cans RR R R R R
Zygomycetes S R R R S R
Notes: aS, susceptible; I, intermediate; R, resistant; SDD, susceptibility depends on the dose; ND, no data. bSusceptible, but few clinical data are available. c10%–15% of C. glabrata 
isolates are resistant to ﬂ  uconazole. dResistant to itraconazole ∼50% and ∼30% of C. glabrata and C. krusei isolates, respectively. e20% of isolates are resistant to amphotericin B.Therapeutics and Clinical Risk Management 2008:4(6) 1266
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for the development of a Candida spp. infection (Puzniak 
et al 2004; Tortorano et al 2004).
Candida infections are associated with a signiﬁ  cant 
mortality rate, particularly among critically ill patients 
(Leleu et al 2002). The crude mortality rate of these infec-
tions has been estimated at 40%–75%, and the mortality 
rate attributable to candidemia at 25%–38% (Nolla-Salas 
et al 1997; Petri et al 1997; Tortorano et al 2004; Almirante 
et al 2005). A review of matched cohort and case-control 
studies has examined the mortality rate that could be linked 
to candidemia (Falagas et al 2006). The data suggested that 
candidemia is indeed associated with a considerable mortality 
rate that can be attributed to the infection itself.
In recent years, the species of Candida that result 
in candidemia have shifted from C. albicans to non-C. 
albicans (NCA). Approximately half of the reported cases 
of candidemia are now caused by NCA species (Pfaller 
et al 2000; Tortorano et al 2004; Almirante et al 2005), and 
several publications have indicated that these cases have 
a worse prognosis than those caused by C. albicans (Ben 
Abraham et al 2004; Klingspor et al 2004; Morgan et al 2005; 
Dimopoulos et al 2008). This increase has been attributed to 
the use of ﬂ  uconazole prophylaxis (Sendid et al 2006). Other 
adverse outcome predictors described in candidemia episodes 
are the length of ICU stay, renal failure, thrombocytopenia, 
hematologic malignancy, and the need for mechanical ventila-
tion or inotropic support (Ben Abraham et al 2004; Almirante 
et al 2005). In a Spanish multicenter study involving ICU 
patients in 28 hospitals, an Acute Physiology and Chronic 
Health Evaluation (APACHE) II score of 20 at the time of 
candidemia was associated with a higher mortality rate (Nolla-
Salas et al 1997), whereas early treatment with antifungal 
medication and the removal of central venous catheters were 
protective against death (Nolla-Salas et al 1997; Almirante 
et al 2005). Furthermore, inadequate empiric antibiotic treat-
ment it is associated with IFIs and a worse prognosis (Parkins 
et al 2007). Two reports have demonstrated a strong associa-
tion between a delay in the start of antifungal therapy and an 
increase in hospital mortality rates (Morrell et al 2005; Garey 
et al 2006); thus, it is necessary to recognize that time is of the 
utmost importance when considering the therapy of patients 
who are at risk for IFIs.
Prophylaxis of Candida infections in ICU
The implementation of targeted antifungal prophylaxis 
has been shown to be effective in certain ICU settings 
(Calandra and Marchetti 2002). Results from controlled 
randomized trials (Eggimann et al 1999; Pelz et al 2001; 
Garbino et al 2002) support the efﬁ  cacy of azole prophylaxis 
in nonneutropenic high-risk ICU patients, diminishing the 
incidence of Candida infection but not mortality.
Three recently published meta-analysis have tried to 
evaluate the impact of fluconazole prophylaxis on the 
incidence of fungal infections and on mortality among 
critically ill surgical patients (Cruciani et al 2005; Shorr 
et al 2005; Playford et al 2006). The meta-analysis by Shorr 
and colleagues (2005) demonstrated that prophylactic 
ﬂ  uconazole administration in surgical ICU patients appears 
to successfully decrease the rate of mycoses, but this strategy 
does not improve survival. The second meta-analysis by 
Cruciani and colleagues (2005) showed that patients who 
received azole prophylaxis (ﬂ  uconazole and ketoconazole) 
experienced a 80% relative risk reduction in candidemia, 
31.5% relative risk reduction in overall mortality, and 79.4% 
reduction in mortality attributable to Candida infections. 
Finally, Playford and colleagues (2006) reported reduction 
of the IFI incidence rate by about 50% and overall mortality 
by about 25%.
Currently, because of the potential for both resistance 
and emergence of non-albicans isolates, clinicians must 
properly consider these issues when evaluating ﬂ  uconazole 
prophylaxis in ICU, although the meta-analyses published 
by Playford and colleagues (2006) describes above showed 
no evidence of epidemiological shifts after ﬂ  uconazole 
prophylaxis.
In addition, it has been criticized that all controlled ran-
domized trials included into the metaanalyses by Playford and 
Cruciani and colleagues were limited by their monocentric 
design and each of them focused on a group of clinically 
distinctive patients.
Under these circumstances, prophylactic use of 
fluconazole in high risk ICU patients cannot be gener-
ally recommended, but should be restricted to patients 
with multiple risk factors for developing IC, for instance 
as Playford recommend, if the cumulative incidence of 
IC in a certain subpopulation of the ICU approaches or 
exceeds 10%, in spite of active prevention, prophylaxis 
should be initiated. Using this approach, the number 
needed to treat to prevent one case of IC ranges between 
17 (for a risk of 11%) and nine patients (for a risk of 
20%). The subgroups of patients who might most benefit 
from prophylaxis in ICU may be patients with upper 
gastrointestinal perforation (Pelz et al 2001; Garbino 
et al 2002), patients with heavy Candida colonization 
(Piarroux et al 2004), and patients with severe acute 
pancreatitis (De Waele et al 2003).Therapeutics and Clinical Risk Management 2008:4(6) 1267
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Empirical antifungal treatment in ICU
Assessing risk
The early identification of risk factors for the devel-
opment of candidemia such as peritonitis, abdominal 
surgery, previous administration of broad-spectrum antibi-
otics, parenteral nutrition, multiple lumen catheters, prior 
Candida spp. colonization, renal replacement therapy, and 
mechanical ventilation (Petri et al 1997; Blumberg et al 2001; 
Alvarez-Lerma et al 2003), has become the cornerstone of 
empiric treatment of fungal infections in the ICU setting in order 
to reduce the high mortality rate associated with these infections 
(Ibanez-Nolla et al 2004; Garnacho-Montero et al 2005).
The Ostrosky-Zeichner prediction rule
In a multicenter retrospective setting, Ostrosky-Zeichner and 
colleagues (2007) created a prediction rule for IC. The rule 
was obtained through analysis of a group of 2890 patients, 
in which incidence of IC was 3% (88 cases). Statistical 
modeling revealed a particularly high risk for patients under 
systemic antibiotic treatment (days 1–3) or with indwelling 
central venous catheter (days 1–3) and at least two of the 
following factors: total parenteral nutrition (days 1–3), any 
dialysis (days 1–3), any major surgery (days −7–0), pancre-
atitis (days −7–0), any use of steroids (days −7–3), or use of 
other immunosuppressive agents (days −7–0). The rule was 
associated with a sensitivity of 34%, a speciﬁ  city of 90%, 
and a PPV and a NPV of 1% and 97%, respectively. This 
rule applies to approximately 10% of patients who stay in 
the unit for 4 days, and approximately 10% of patients to 
whom this rule is applied will develop proven or probable 
IC. In this study, patients with any combination of diabetes 
mellitus, new-onset hemodialysis, use of total parenteral 
nutrition, or receipt of broad-spectrum antibiotics had an IC 
rate of 16.6%. This compared with a rate of 5.1% in patients 
who lacked these characteristics (P = 0.001). Fifty-two 
percent of patients who stayed in the ICU for 4 days met 
this rule, and the rule captured 78% of patients who eventu-
ally developed IC.
The Candida score
A Spanish group reported on the development of a bedside 
scoring system that allows early antifungal treatment when 
candidemia is suspected in nonneutropenic ICU patients 
(Leon et al 2006). This “Candida score” is based on the 
predictive value of previously reported risk factors. Using 
a logistic regression analysis and adjusting for possible 
confounding variables, the authors found several factors to 
be independently associated with a greater risk for proven 
candidal infection. The scores for the individual factors 
were: parenteral nutrition (+0.908), prior surgery (+0.997), 
multifocal Candida colonization (+1.112), and severe 
sepsis (+2.038). The authors concluded that a “Candida 
score” of 2.5 could accurately select patients who would 
beneﬁ  t from early antifungal treatment (sensitivity 81%, 
speciﬁ  city 74%).
Pre-emptive antifungal treatment 
in the ICU
Poor outcomes are, in part, associated with difﬁ  culties in 
establishing the microbiologic diagnosis at an early stage 
of infection. Blood culture results are positive in only 50% 
of invasive Candida and Fusarium infections, and are very 
rarely positive in cases of IA. Cultures of bronchoalveolar 
lavage ﬂ  uid or brushing specimens are positive in 50% 
of subjects with invasive pulmonary aspergillosis. Finally, 
positive cultures of specimens from nonsterile body sites 
may be related to either colonization or infection, and 
distinguishing between these can be difﬁ  cult. Nonculture-
based diagnostic tests may provide a useful adjunct to these 
more traditional approaches.
Corrected colonization index
Piarroux and colleagues (2004) assessed the efﬁ  cacy of a 
pre-emptive antifungal therapy in preventing proven can-
didiasis in critically ill surgical patients, using a corrected 
colonization index (CCI) (ratio of highly positive samples 
to the total numbers of samples cultured) to measure the 
intensity of Candida mucosal colonization. Patients with 
a CCI value of 0.4 received early pre-emptive antifungal 
therapy with ﬂ  uconazole, and the incidence of ICU-acquired 
proven candidiasis decreased signiﬁ  cantly from 2.2 to 0%. 
However, it is possible that the overload of samples sent to 
the microbiology laboratory could limit the widespread use 
of this approach.
Targeted treatment of invasive candidiasis 
in the ICU
The best ﬁ  rst-line treatment for candidemia in critically ill 
patients remains controversial. Clinical studies have shown 
that amphotericin B (AmB), ﬂ  uconazole, echinocandins, 
and voriconazole have similar efﬁ  cacy in the treatment of 
Candida bloodstream infections (Rex et al 1994; Phillips 
et al 1997; Mora-Duarte et al 2002; Kullberg et al 2005). In 
accordance with the last IDSA guidelines (Pappas et al 2004), 
many experts favor initial treatment with AmB in severely ill 
or clinically unstable patients; although the recent published Therapeutics and Clinical Risk Management 2008:4(6) 1268
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Swiss guidelines for fungal infections (Fluckiger et al 2006) 
do not support this statement. However, its renal toxicity 
could present a serious problem in these individuals, which 
may often preclude its use as ﬁ  rst-line therapy (Bates et al 
2001; Blot et al 2002).
While the triazole, ﬂ  uconazole, may be selected on the 
basis of its efﬁ  cacy and safety (Rex et al 1994; Phillips 
et al 1997), the increasing frequency of patients infected 
with Candida strains that are resistant to this drug high-
light the need for initial treatment with a broader-spectrum 
agent, at least until the Candida spp. is identiﬁ  ed, in order 
to avoid inadequate antifungal treatment and an associ-
ated increased mortality rate (Zaragoza and Peman 2006). 
Results from the ﬁ  rst randomized, prospective, multicenter 
study in nonneutropenic patients with candidemia who were 
treated with either voriconazole alone or AmB deoxycholate 
followed by ﬂ  uconazole have demonstrated equivalence of 
these two regimens with regard to efﬁ  cacy and mortality 
rates (Kullberg et al 2005). Response rates were similar in 
the voriconazole and AmB/ﬂ  uconazole arms; however, for 
C. tropicalis infection, the response rate was signiﬁ  cantly 
higher in the group treated with voriconazole, despite in vitro 
susceptibility of these strains to AmB. These results can be 
easily applied to critically ill patients as approximately half 
of the patients included in the study were admitted to an ICU. 
The only limitation to the use of intravenous voriconazole 
in these patients could be the accumulation and toxicity 
of its excipient (cyclodextrin) in severe renal dysfunction, 
although there are no data regarding this concern in patients 
undergoing renal replacement therapy.
Published reports suggest that caspofungin is equiva-
lent in efﬁ  cacy to standard therapy with AmB in the treat-
ment of Candida infections (Mora-Duarte et al 2002). 
Mora-Duarte and colleagues (2002) compared caspofungin 
to AmB in the treatment of IC in nonneutropenic (n = 200) 
and neutropenic patients (n = 24). Caspofungin was as 
efficacious as AmB, with favourable response rates of 
73.4% and 61.7%, respectively. Micafungin has become 
the second available echinocandin approved for use in the 
USA and Japan for the treatment of esophageal candidiasis 
and prophylaxis in subjects with neutropenia (Chandrasekar 
and Sobel 2006). Recently, two different studies have been 
published for invasive candidiasis (Kuse et al 2007; Pappas 
et al 2007). In these studies, micafungin was as effective 
as liposomal AmB (Kuse et al 2007) or caspofungin (Pappas 
et al 2007) as ﬁ  rst-line treatment of candidemia and IC and 
caused fewer adverse events than liposomal AmB. Finally, 
anidulafungin is the only antifungal compound that has been 
able to demonstrate superiority over ﬂ  uconazole in IC (Reboli 
et al 2007), although we must be cautious with the results 
presented as the study involved was powered a priori for 
equivalency. However, anidulafungin’s efﬁ  cacy and safety 
proﬁ  le could indicate that it should be readily considered as 
a ﬁ  rst-line option for the treatment of IC.
In the last years, some publications have shown a shift 
toward the use of antifungal drugs other than ﬂ  uconazole 
due to the increasing number of non-C. albicans (NCA) 
isolates (Sendid et al 2006; Zaragoza and Peman 2006). 
Consequently, the application of an early de-escalation 
therapy in critically ill patients with fungal infection should be 
recommended (Zaragoza and Peman 2006). For this reason, 
voriconazole (due to its broad spectrum and good proﬁ  le in 
the ICU setting), caspofungin, anidulafungin and micafungin 
(particularly in renal dysfunction) could be attractive options 
in critically ill patients. Finally, the choice of antifungal drug 
must be based on the individual characteristics of the patient, 
and particularly focus on the presence of renal or hepatic 
failure, hemodinamic instability and possible interactions 
with other drugs. The presence of hemodynamic instability is 
a mayor factor for choosing empirical therapy. This fact has 
been considered by the recent guidelines published enhanc-
ing a tailored therapy (de-escalation) especially with severe 
sepsis or septic shock (Pappas et al 2004; Fluckiger et al 
2006). All these guidelines heavily recommend, including 
last ongoing IDSA guidelines, the use of echinocandins in 
noneutropenic patients with IC when hemodynamic inesta-
bility was present. The high rate of clinical success of these 
agents in candidemia, their low toxicity, their excellent safety 
proﬁ  le and their broad spectrum against non-albicans spp. 
makes this recommendation feasible. A recent publication 
has corroborated the use of caspofungin in critically ill 
patients (DiNubile et al 2007).
In conclusion, IFIs, especially in the critical care setting, 
have become an excellent target for prophylactic, empiric, 
and pre-emptive therapy interventions. Table 2 summarizes 
the antifungal therapy strategies in ICU patients.
Prophylaxis, empirical, pre-emptive 
or targeted therapy, which is the 
best in hematological patients?
Hematological patients are prone to IFI since most of them 
receive myelotoxic chemotherapy and usually have more 
than one of well-known risk factors for IFI (eg, long-lasting 
neutropenia, older age, active cancer, corticosteroid therapy, 
administration of broad spectrum antibiotics, allogeneic 
HSCT, central venous catheter, organ dysfunction). Therapeutics and Clinical Risk Management 2008:4(6) 1269
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These patients are usually polymedicated and are thus 
exposed to harmful drug interactions. Furthermore, it is 
important to emphasize that the same individual patient 
will be at risk at several time points through the entire treat-
ment plan for his/her underlying disease. Thus, the planned 
antineoplastic treatment should be kept in mind when design-
ing antifungal strategies for hematological patients.
Prophylaxis of IFI 
in hematological patients
Historically, outcomes for IFI have been disappointing and 
associated with a high mortality rate. Because of this, pro-
phylaxis has been the ﬁ  rst option to consider in hematological 
patients. Since the early 90’s, ﬂ  uconazole prophylaxis has 
reduced infections caused by Candida spp. but dramatic 
changes in the epidemiology of IFI have occurred, with 
Aspergillus spp. and NCA species becoming increasingly 
common. These changes have affected the selection of 
antifungals for first-line or prophylactic use, as not all 
agents have the spectrum of activity required. At this point, 
it should be noted that evidence based recommendations 
are to be interpreted with caution and so we should always 
consider the moment when they were formulated. For 
example, beneﬁ  t of antifungal prophylaxis with ﬂ  uconazole 
(400 mg/day) in allogeneic HSCT recipients continues to 
be an A-I recommendation but today C. albicans is not 
longer the predominant pathogen in this setting. However, 
newer azoles have the potential to provide protection against 
mould infections that are difﬁ  cult to treat once they occur. 
Two large randomized, ﬂ  uconazole- or itraconazole-based 
controlled clinical trials in acute leukemia patients (Cornely 
et al 2007b) and in HSCT recipients with graft-versus-host 
disease (GVHD) (Ullmann et al 2007) have demonstrated 
the efﬁ  cacy of oral posaconazole (200 mg thrice daily) for 
reducing invasive mould infections. Ideally prophylaxis 
should usually be initiated in parallel with the administration 
of cytotoxic therapy in order to ensure a protective effect at 
the time of maximal neutropenia and intestinal epithelial 
damage, but concerns over drug interactions make advisable 
to start triazole-based prophylaxis after the administration 
of cytotoxic therapy, especially in HSCT recipients. The 
ability to switch from the oral to an intravenous formulation 
for the same antifungal product in the setting of severe oral 
mucositis is an advantage. Both oral solution and intravenous 
formulation of itraconazole are suitable for prophylaxis in 
high-risk patients, but compliance with the oral solution 
is poor (Marr et al 2004b). A preliminary report of a large 
trial to assess prophylactic voriconazole in allogeneic HSCT 
recipients (oral or IV 200 mg BID) was recently presented 
(Wingard et al 2007). Prophylaxis with micafungin (van 
Burik et al 2004) and caspofungin (Mattiuzzi et al 2006) have 
been studied at daily IV doses of 50 mg but echinocandins 
are preferred in the clinical practice for therapy instead of 
prophylaxis. The end of prophylaxis should be dictated by 
the termination of the speciﬁ  c risk. Mould-active prophylaxis 
may require administration into the late post-engraftment 
period in allogeneic HSCT for those patients with higher 
Table 2 Antifungal therapy strategies in ICU patients
Strategy Antifungal agent References
Prophylaxis No generally recommended. Patients with 
upper gastrointestinal perforation, heavy 
Candida colonization or with severe acute 
pancreatitis might be beneﬁ  ted
Fluconazole Pelz et al 2001; Garbino et al 2002; De 
Waele et al 2003; Piarroux et al 2004
Empirical Use of “Candida score” or the 
Ostrosky-Zeichner prediction rule
De-escalation therapy (*), the choice 
of antifungal drug must be based on 
the individual characteristics of the 
patient
Leon et al 2006; Ostrosky-Zeichner 
et al 2007
Pre-emptive Based on detection of galactomannan, 
(1,3)-β-D-glucan or C. albicans germ tube 
antibodies
De-escalation therapy (*), the choice 
of antifungal drug must be based on 
the individual characteristics of the 
patient
Ostrosky-Zeichner et al 2005; 
Zaragoza et al 2006; Meersseman 
et al 2008
Targeted Based on sterile site culture results De-escalation therapy (*), the choice 
of antifungal drug must be based on 
the individual characteristics of the 
patient (**)
Rex et al 1994; Phillips et al 1997; 
Mora-Duarte et al 2002; Kullberg et al 
2005; Zaragoza and Peman 2006; Kuse 
et al 2007; Pappas et al 2007
Notes: *An early broad-spectrum antifungal agent is initially prescribed, switching to a narrower-spectrum drug (ﬂ  uconazole) when mycological identiﬁ  cation and susceptibility 
studies are provided. **Focus on the presence of renal or hepatic failure, hemodynamic instability and possible interactions with other drugs.Therapeutics and Clinical Risk Management 2008:4(6) 1270
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risk due to acute or chronic GVHD requiring augmented 
immunosuppressive therapy (Marr et al 2004b; Ullmann 
et al 2007). Finally, the use of aerosolized lipid-based 
formulations of AmB may prove to be useful as prophylaxis 
for mould infection in the respiratory tract, the major portal 
of entry of fungal conidia (Rijnders et al 2008). The combi-
nation of nebulized AmB with ﬂ  uconazole is an interesting 
approach to avoid drug interactions (eg, in patients receiving 
vinca alkaloids).
Empirical therapy of IFI in hematological 
patients
For lower risk patients or when IFI is suspected in patients 
receiving prophylaxis, empirical antifungal therapy is 
often employed following a predeﬁ  ned duration of fever. 
During the early 1980s one quarter to one third of severely 
neutropenic cancer patients with persistent or relapsing fever 
despite broad-spectrum antibacterial therapy developed IFI. 
Empirical AmB deoxycholate reduced the incidence of IFI and 
overall mortality by 50%–80% and 23%–45%, respectively. 
Fever is a poorly predictive surrogate upon which to base an 
intervention such as empirical antifungal therapy (De Pauw 
2005). Although a substantial number of leukemia patients 
and HSCT recipients are given empirical antifungal therapy, 
proven IFI occurs in only 2% to 15% (Kanda et al 2000; 
Bow et al 2002; Ullmann et al 2002; Cornely et al 2007b) 
suggesting that the current guidelines (Hughes et al 2002) 
based upon persistent neutropenic fever are signiﬁ  cantly 
ﬂ  awed and may result in unjustiﬁ  able excess treatment-related 
toxicities and resource expenses (De Pauw 2005).
Currently, caspofungin and liposomal AmB are the 
ﬁ  rst-line option for treating patients with febrile neutrope-
nia (Walsh et al 1999, 2004). The role of voriconazole as 
an empirical treatment for patients with febrile neutropenia 
remains unresolved, and in fact, voriconazole is currently 
not licensed for this indication. The results of a large, 
international, multicenter, randomized study that compared 
voriconazole with liposomal AmB for the empirical treatment 
of febrile neutropenic patients have been controversial 
(Walsh et al 2002). According to the predeﬁ  ned end point 
of this study (noninferiority), voriconazole did not achieve 
this goal relative to liposomal AmB; the overall success 
rates were 26% and 30.6%, respectively. Breakthrough 
fungal infections occurred in eight patients (1.9%) in the 
voriconazole group compared with 21 patients (5%) in the 
liposomal AmB group (P = 0.02). However, more patients 
died in the voriconazole group and a claimed signiﬁ  cant 
reduction in the number of breakthrough fungal infections 
disappeared when patients arbitrarily excluded from analysis 
by the trial authors were included (Jorgensen et al 2006).
Continuous infusion administration AmB has been 
proposed over the past few years, claiming it could reduce 
the risk of nephrotoxicity associated to this agent. The pre-
liminary results of an open study, including 80 neutropenic 
patients during 4 hour infusion versus continuous infusion, 
suggest more advantages for continuous infusion. A signiﬁ  -
cantly lower incidence in reactions related with the infusion 
was found in the case of continous administration, which also 
favored the creatinine clearance values (Eriksson et al 2001). 
Another cohort study on 81 febrile neutropenic hematologi-
cal patients with a higher IFI risk, evaluated the administra-
tion of AmB in intermittent infusion during 4h, compared 
to a continuous infusion (Peleg and Woods 2004). Kidney 
failure was seen in 45% and 10% of the patients, respectively 
(OR 0.14; IC 95% 0.04–0.5; P0.001). The result was 
similar in patients with allogeneic transplant and in those 
which were given other nephrotoxic drugs. A multivariate 
logistic regression showed that the continuous infusion was 
the only variable signiﬁ  cantly associated to kidney failure, 
with a protective effect.
Nevertheless, the use of continuous infusion is still con-
troversial. Whilst some authors defend this strategy before 
opting for lipid or liposomic formulations (Johnson 2004; 
Schneemann and Bachli 2004), others do not consider it 
totally acceptable because of limited experience. Altmanns-
berger and colleagues (2007), when repeating the experience 
provided by Peleg and Woods (2004), found no signiﬁ  cant 
advantages between intermittent and continuous infusion in 
patients with a high IFI risk.
Pre-emptive therapy of IFI
in hematological patients
A more reﬁ  ned approach is pre-emptive therapy where 
treatment is only initiated upon positive identiﬁ  cation of a 
surrogate marker of infection in combination with clinical 
and radiological signs. This pre-emptive therapy will subject 
fewer patients to toxic and expensive treatments. The interest 
in this strategy is based upon the observation that early detec-
tion is associated with better outcomes. A study in acute 
leukemia patients receiving ﬂ  uconazole prophylaxis exam-
ined an algorithm-based pre-emptive approach based upon 
serial diagnostic testing and clinical monitoring (Maertens 
et al 2005). Only patients with 2 positive serum GM assays 
or CT and or bronchoscopic evidence for mould infection 
received antifungal therapy. A total of 41 of 117 febrile 
neutropenic episodes (35%) had persistent neutropenic Therapeutics and Clinical Risk Management 2008:4(6) 1271
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fever; however, only 9 patients (22% of the 41 persistent 
neutropenic fevers; 8% of the original febrile neutropenic 
episodes) satisﬁ  ed the pre-deﬁ  ned criteria for antifungal ther-
apy. Despite these promising observations, the appearance of 
a clinical or radiological marker such as a suggestive nodular 
pulmonary inﬁ  ltrate on computerized thoracic tomography 
in a high-risk patient will compel the anxious physician to 
initiate antimould therapy independent of molecular markers. 
Pre-emptive strategies are intellectually attractive because 
they combine in an elegant manner newer diagnostic tools 
in order to give antifungal therapy only to patients who 
really deserve it. However, in the real world, they are dif-
ﬁ  cult to carry out. Furthermore, nonculture methods such 
is serum GM assay lose diagnostic power if an anti-mould 
prophylaxis is given, which in turn will be given to higher 
risk patients. Thus pre-emptive therapy based on sensitive 
diagnostic non-culture methods needs further validation in 
larger randomized trials before becoming a standard.
Targeted therapy of IFI in hematological 
patients
Targeted therapy is used in patients with conﬁ  rmed IFI. Again 
hematological patients deserve especial consideration as they 
are commonly at high risk of hemorrhagic complications 
that render them unﬁ  t for aggressive diagnostic procedures 
including biopsies. Therefore many suspected cases will be 
diagnosed as probable IFI at the most.
A study comparing voriconazole to conventional AmB 
in 277 patients (Herbrecht et al 2002) demonstrated higher 
response rates among voriconazole recipients (52.8% versus 
31.6%), a 67% improvement. Patients with early lesions 
characterized by pulmonary nodules with halos had higher 
treatment response rates (52.4% versus 29.1%) (Greene 
2005). Moreover, a survival advantage for voriconazole 
recipients was observed (70.8% compared to 57.9%, 
P = 0.024). Despite this, response among allogeneic HSCT 
recipients remained suboptimal (32.4% for voriconazole ver-
sus 13.3% for conventional AmB). A study of dose-intense 
(10 mg/kg/d for 14 days followed by 3 mg/kg/d vs 3 mg/kg/d) 
of liposomal AmB as primary therapy for IA demonstrated 
similar response rates (46% vs 50%, respectively), but more 
nephrotoxicity (31% versus 14%), hypokalemia (30% versus 
16%), and higher mortality in the dose-intense group (41% 
versus 28%) (Cornely et al 2007a). Based on this experience, 
the value of dose-intensity for IA appears limited.
Poor response rates for primary and salvage monotherapy 
therapy for IFI and the availability of increasingly safer 
agents with differing mechanisms of action have prompted 
hematologists to use early combination therapy. Arguments 
for considering combination therapy include enhanced 
fungal killing (synergy), an enhanced spectrum of activity, 
prevention of development of resistance, and reduction of 
drug-related toxicities (Kontoyiannis and Lewis 2004). 
Favorable responses were observed among HSCT patients 
failing polyene-based therapy for IA with a combination of 
voriconazole and caspofungin compared to voriconazole 
monotherapy (Marr et al 2004a). Recently, a French mul-
ticenter randomized study comparing combination therapy 
with liposomal AmB (3 mg/kg/d) plus caspofungin (70 mg 
day 1 and 50 mg/d thereafter) versus high-dose liposomal 
AmB monotherapy (10 mg/kg/d) for primary treatment of 
IA was published (Caillot et al 2007). A favorable over-
all response was observed in 67% combination therapy 
recipients compared to 27% high-dose therapy recipients 
(P = 0.028). The results of this small pilot, representing the 
ﬁ  rst prospective study of combination therapy in IA, are 
encouraging but need conﬁ  rmation. Combination antifun-
gal therapies are expensive and potentially toxic and there 
are limited well-designed randomized-controlled trials to 
guide the practicing clinician faced with managing these 
problems.
In conclusion, risk-adapted prophylaxis is the best option 
in hematological patients. Table 3 resumes the antifungal 
therapy strategies in these patients.
Prophylaxis, empirical, pre-emptive 
or targeted therapy, which is the 
best in solid organ transplant 
recipients (SOT)?
Renal, liver, heart, and lung transplantation are now consid-
ered to be the standard therapeutic interventions in patients 
with end-stage organ failure. The use of newer more potent 
immunosuppressive regimens as well as widespread use of 
antifungal drugs has changed the landscape of fungal infec-
tions. The incidence of invasive mycoses following SOT 
ranges from 5% to 42% depending on the organ transplanted 
(Marik 2006; Singh 2004; Solé and Salavert 2007). Fungal 
infections in SOT recipients continue to be a signiﬁ  cant cause 
of morbidity and mortality. The clinical and epidemiological 
characteristics of IFIs in recipients of nonpulmonary solid 
organ transplantation (NP-SOT) are very different from 
which occurs in the patients with lung transplantation (LT) 
or HSCT. The incidence of invasive mycoses varies with type 
of SOT, though Candida spp. and Aspergillus spp. account 
for most IFI in SOT recipients (Silveira and Husain 2007). Therapeutics and Clinical Risk Management 2008:4(6) 1272
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Liver transplant recipients have highest reported incidence 
of Candida infections while LT recipients have highest rate 
of Aspergillus infections (Singh 2005; Singh and Paterson 
2005; Solé et al 2005; Solé and Salavert 2008). Recent epide-
miological studies suggest the emergence of resistant strains 
of Candida as well as mycelial fungi other than Aspergillus 
in these patients. Moreover, signiﬁ  cant percentages of fungal 
infections are occurring late in the course of transplantation. 
SOT recipients also are at risk for Cryptococcus infections 
(Singh et al 2007) and reactivation of endemic mycoses 
such as histoplasmosis and coccidiomycosis.. Emergence of 
newer and more potent antifungal agents with lower toxicity 
potentially changes the concept of antifungal prophylaxis 
(van Burik 2005; Metcalf and Dockrell 2007).
Prophylaxis and pre-emptive therapy 
of IFI in solid organ transplant patients
Several prophylactic strategies with antifungal drugs have 
been reported to result in a decreased incidence and mortality 
of fungal disease in LT recipients (Covarrubias and Milstone 
2005; Husain et al 2006b; Magill and Dropulic 2006); 
however, there has not been a uniform approach, data are 
limited, and besides there is a considerable variation in anti-
fungal prophylaxis practices among LT centres throughout 
the world. The majority of LT programs are using universal 
antifungal prophylaxis in the postoperative period; about 
30% use a pre-emptive approach for patients with pre- and/or 
post-transplant fungal airway colonization. As the antifungal 
agent used as the duration of prophylaxis varies substantially 
from center to center (Husain et al 2006b). It is clear that there 
is considerable uncertainty to which approach (prophylaxis 
or pre-emptive therapy) is most appropriate, which agent is 
the best, and what duration of prophylaxis or pre-emptive 
therapy is needed. Antifungal prophylaxis in LT recipients 
should be taken into account the incidence of colonization, 
anastomoses healing, chronic rejection, and the time of LT, 
thus providing a rationale for the duration of therapy.
To prevent invasive pulmonary aspergillosis, multiple 
strategies and antifungal drugs have been utilized such as oral 
itraconazole, voriconazole or aerosolized AmB used alone 
or in combination. Aerosolized medication regimens are an 
attractive option, as drug interactions and systemic toxici-
ties are likely to be limited (Drew 2006). Lipid preparations 
of AmB appear to be ideal for inhalational administration; 
however, there are not rigorous pharmacokinetic studies in 
LT recipients, to determine the appropriate dose and sched-
ule of their administration. Monforte and colleagues have 
demonstrated that aerosolized AmB and lipid preparations 
of AmB are safe and achieve high concentrations in BAL 
ﬂ  uid for the ﬁ  rst 24 hours and 14 days, respectively, follow-
ing nebulization (Monforte et al 2003, 2005). These lipid 
formulations let a delayed administration (every 7–14 days), 
which is rebounded and better accomplished by patient. 
Several centers have reported on the safety of aerosolized 
AmB with a variety of dosing regimens (Reichenspurner et al 
1997; Calvo et al 1999; Monforte et al 2003), and others with 
Table 3 Antifungal therapy strategies in hematological patients
Strategy Antifungal agent References
Prophylaxis High risk patients*:
Intermediate risk patients**:
Itraconazole or
Posaconazole or
Voriconazole
Fluconazole
Jarque et al 2004; Marr et al 2004b; 
Cornely et al 2007b; Ullmann et al 2007; 
Wingard et al 2007
Empirical Severely neutropenic cancer patients 
with persistent or relapsing fever despite 
broad-spectrum antibacterial therapy
Liposomal AmB or
Caspofungin
Hughes et al 2002; Walsh et al 1999, 2004
Pre-emptive Based on GM assays or CT 
or bronchoscopic cultures
Liposomal AmB or
Caspofungin or
Voriconazole
Maertens et al 2005
Targeted Based on sterile site culture results Voriconazole
Combination therapy
Herbrecht et al 2002; Marr et al 2004a; 
Caillot et al 2007
Notes: *Acute leukemia patients, Allogenic HSCT recipients, autologous HSCT recipients, previous episode of IFI, rescue chemotherapy for acute leukemia patients and severe 
aplastic anemia. **Autologous HSCT recipients, acute linfoblastic leukemia, rescue therapy for myeloma and lymphomas.Therapeutics and Clinical Risk Management 2008:4(6) 1273
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aerosolized AmB lipid formulations (Palmer et al 2001; Drew 
et al 2004; Lowry et al 2007). Our group has used aerosolized 
AmB as part of the post-LT protocol since 1994 (Calvo et al 
1999). Since three years ago we also are using AmB lipid 
complex, with the same respiratory tolerability and safety 
that aerosolized AmB, but AmB lipid complex results more 
comfortable for long periods of time (50 mg inhaled/ weekly), 
and patients have better adherence to treatment. Recently, in 
vitro suitability of caspofungin for aerosol administration has 
been characterized (Wong-Beringer et al 2005). Caspofungin 
solution appeared to have physicochemical and aerodynamic 
characteristics suitable for aerosolization. However, further 
in vivo testing is warranted. Although the incidence of IFI 
seems to be reduced with aerosolized AmB prophylaxis, the 
efﬁ  cacy of this approach has not been determined in a large 
prospective clinical trial. Furthermore, without detectable 
levels of AmB in the circulation, extrapulmonary fungal 
infections may not be prevented by this strategy. Besides, it is 
important to take into consideration the type of delivery sys-
tems used for inhaled drugs (Corcoran et al 2006; Hagerman 
et al 2006). In addition, contamination of the nebulization 
systems used in the prophylaxis with AmB nebulized in LT 
has been described (Monforte et al 2003). The contamination 
of the nebulizing systems may be the origin of respiratory 
infections and it is frequent when no strict cleaning and 
disinfection protocol is followed.
In conclusion, aerosolized antifungal therapy is a promis-
ing route of drug delivery for pulmonary aspergillosis due 
to attainment of high localized concentrations (Mohammad 
and Klein 2006; Solé and Nieto 2007).
Respect to oral prophylaxis, recently a study that 
examined the efﬁ  cacy and toxicity of a strategy of universal 
de novo antifungal prophylaxis with voriconazole compared 
to targeted antifungal prophylaxis has been published (Husain 
et al 2006a). The main ﬁ  nding of this study was that the 
overall rate of IA at 1 year decreased to 1.5% with universal 
voriconazole prophylaxis as compared to 23.5% with a tar-
geted prophylaxis strategy. Interestingly, the rate of Candida 
colonization, particularly non-albicans spp. in the voricon-
azole group was signiﬁ  cantly higher. In the voriconazole 
prophylaxis cohort, 27% of the LT recipients had normal 
liver enzymes throughout the course of the study. The main 
handicap of this azole therapy is the strong interaction with 
immunosuppressors that obliges to monitoring calcineurin 
inhibitors to avoid toxicity or rejection. Other interesting 
ﬁ  nding was that universal voriconazole prophylaxis did 
not increase the rate of non-Aspergillus fungal infections 
(specially, zygomycosis).
Available echinocandins (caspofungin, micafungin, 
anidulafungin) may have an important role in prophylaxis 
because of their antifungal proﬁ  le, pharmacokinetics and 
security; however, they are expensive and need intravenous 
administration.
Another question is how long should be prophylaxis 
maintained? The majority of centers agree to apply universal 
prophylaxis during ﬁ  rst period post transplant (3 months) after 
this time, each center use a tailored prophylaxis. Besides, it is 
recommended to use nebulized antifungal prophylaxis and/or 
preemptive therapy with antifungal agents (voriconazole) 
in patients with chronic rejection and respiratory samples 
positive for Aspergillus, even without clinical or radiological 
signs, mainly in single LT patients due to the high risk of IA 
(Solé et al 2005). This preemptive treatment should last for 
at least 6 months, the time period over which colonization 
has been shown to precede disseminated infection (Singh 
and Husain 2003) and in some cases for life. Table 4 shows 
antifungal therapy strategies in LT patients.
Due to the difﬁ  culty in obtaining a proven diagnosis of 
IFI, empiric and pre-emptive therapy plays an important role 
in NP-SOT patients (Table 5) (Leather and Wingard 2006; 
Bow 2008). As it is mentioned in Table 6, some of NP-SOT 
recipients have additional risk factors that increases the prob-
ability of suffer an IFI caused by Aspergillus spp. (Echaniz-
Quintana et al 2004; Singh 2005; Singh et al 2006b, 2006c). 
For this reason, the incorporation of a strategy of antifungal 
prophylaxis adapted-to-risk is accepted and high risk patients 
need to be identiﬁ  ed in order to prevent the development of 
the disease (Playford et al 2004; Castroagudin et al 2005; 
Hellinger et al 2005).
Since the IFI risk is lower in the cardiac and kidney 
recipient patients, we will make reference mainly to patients 
with orthotopic liver transplantation (OLT) as paradigm of 
the indication of antifungal prophylaxis in NP-SOT patients. 
However, prophylaxis of candidiasis in SOT recipients 
is a challenging topic. Strategies to prevent IC should be 
based on institutional trends and, when appropriate, should 
target high-risk patients only (Singh 2000). Only a few 
well-designed studies have been conducted and all of the 
controlled trials were performed in liver transplant recipients. 
Oral prophylaxis with nonabsorbable antifungal agents 
(nystatin, clotrimazole, AmB) has shown inconsistent results 
(Wiesner et al 1988; Arnow et al 1996; Hjortrup et al 1997; 
Hellinger et al 2002). Two randomized controlled trials 
have shown the efﬁ  cacy of ﬂ  uconazole in the prophylaxis 
of IC. In one study, comparing ﬂ  uconazole 100 mg/day 
for the ﬁ  rst 4 weeks following liver transplantation to oral Therapeutics and Clinical Risk Management 2008:4(6) 1274
Zaragoza et al
Table 4 Antifungal therapy strategies in lung transplantation (LT) recipients
Strategy Antifungal agents References
Prophylaxis Generally recommended in the postoperative 
period
Voriconazole or
Amphotericin B (intravenous 
or aerosolized)
Calvo et al 1999; Monforte et al 2005; 
Husain et al 2006a; Drew 2006;
Lowry et al 2007
Pre-emptive Patients with pre- and/or post-transplant 
fungal airway colonization
Patients with chronic rejection and 
respiratory samples positive for Aspergillus, 
mainly in single LT patients
Detection of galactomannan antigen of 
Aspergillus, (1,3)-β-D-glucan or C. albicans 
germ tube antibodies are not reliable 
methods with usefulness sufﬁ  ciently 
demonstrated in the LT
Voriconazole or
Amphotericin B (intravenous 
or aerosolized)
Singh and Husain 2003;
Sole et al 2005
Targeted Based on sterile site culture results or 
non-absolutely sterile samples (respiratory 
specimens) processed by semi or quantitative 
methods and considered clinically signiﬁ  cant
AND/OR
Based in histological studies of biopsies and 
other clinical specimens obtained by instru-
mental or chirurgic procedures (respiratory 
and non-respiratory samples)
Voriconazole or
Amphotericin B or
Echinocandins
Combination therapy (triazole plus 
echinocandin) in those patients with 
LT and renal failure or infected by 
A. fumigatus
Herbrecht et al 2002;
Singh et al 2006a
Table 5 Antifungal therapy strategies in recipients of nonpulmonary solid organ transplantation (NP-SOT)
Strategy Antifungal agents References
Prophylaxis Universal prophylaxis is not recommended
Antifungal prophylaxis adapted-to-risk is 
reasonable
High-risk NP-SOT recipients need
 to be identiﬁ  ed in order to prevent 
the development of IFI
Oral prophylaxis with nonabsorbable 
antifungal agents (nystatin, 
clotrimazole, amphotericin B) has 
shown inconsistent results.
Azoles (ﬂ  uconazole, itraconazole) or
Amphotericin B (lipid formulations) 
or Echinocandins (caspofungin)
Lumbreras et al 1996; Winston 
et al 1999; Singh et al 2001; 
Winston and Busuttil 2002; Fortun 
et al 2003, 2007; Sharpe et al 2003; 
Hellinger et al 2002, 2005; Munoz 
et al 2004; Castroagudin et al 2005
Pre-emptive Strategy not sufﬁ  ciently validated in these 
patients
Detection of galactomannan antigen of 
Aspergillus, (1,3)-β-D-glucan or C. albicans germ 
tube antibodies are not usefulness in NP-SOT 
recipients
Azoles or
Amphotericin B
Akamatsu et al 2007; Perkins 2007
Targeted Based on sterile site culture results or 
nonabsolutely sterile samples (respiratory 
specimens) processed by semi or quantitative 
methods and considered clinically signiﬁ  cant
AND/OR
Based in histological studies of biopsies 
and other clinical specimens obtained 
by instrumental or chirurgic procedures 
(respiratory and non-respiratory samples)
Azoles or
Amphotericin B or
Echinocandins
Combination therapy (triazole plus 
echinocandin) in patients with SOT 
and renal failure or infected by 
A. fumigatus
Herbrecht 2002; Singh et al 2006aTherapeutics and Clinical Risk Management 2008:4(6) 1275
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nystatin, ﬂ  uconazole was associated with a reduction in 
Candida colonization and superﬁ  cial infections, as well as 
a trend toward reduction of invasive infections (Lumbreras 
et al 1996). In a randomized, placebo-controlled study, 
ﬂ  uconazole 400 mg/day for 10 weeks after liver transplanta-
tion prevented most types of Candida infection, except those 
caused by C. glabrata and C. krusei. In another double blind 
randomized control trial itraconazole decreased the rate of 
fungal infection from 24% to 4% in liver transplant recipients 
(Sharpe et al 2003). A recently published meta-analysis 
showed that antifungal prophylaxis in liver transplant recipi-
ents signiﬁ  cantly reduced the total episodes of superﬁ  cial 
and IFI caused by yeasts (at least for C. albicans), as well 
as mortality attributable to fungal infections; however, it did 
not affect overall mortality or the need for empirical antifun-
gal treatment (Cruciani et al 2006). Compared to controls, 
patients receiving prophylaxis experienced a higher propor-
tion of episodes of Candida non-albicans infections. Prophy-
lactic strategies against invasive Candida infections should 
be reassessed periodically because risk factors continue to 
evolve in liver transplant recipients (Husain et al 2003).
Antifungal prophylaxis to prevent IA remains an 
unsettled issue in NP-SOT. To date, no prospective random-
ized studies have demonstrated that antifungal prophylaxis 
Table 6 Etiological and clinical characteristics of IFI according to the type of SOT
Type of transplant Incidence of IFI (%) Usual etiologic agent (s) Variables portending higher 
risk of IA
Mortality 
(%) of IA
Renal 0–20 76%–95% Candida (mainly 
urinary tract infections),
Graft failure requiring hemodialysis, 
high level and prolonged duration 
of corticosteroids
77
0%–25% Aspergillus
Heart 5–20 70%–90% Aspergillus, 
8%–25% Candida
Isolation of Aspergillus species 
in respiratory tract cultures, 
reoperation, post-transplant 
hemodialysis, CMV disease
78
Liver 5–40 35%–0% Candida, 9%–45% 
Aspergillus
Retransplantation, renal failure 
(particularly requiring renal 
replacement therapy), fulminant 
hepatic failure as an indication 
for transplantation, primary 
allograft failure, high transfusion 
requirements, use of monoclonal 
antibodies,
87
Lung/Heart–Lung 10–45 43%–72% Candida, 
25%–50% Aspergillus
Single lung transplant, CMV 
infection, rejection and augmented 
immunosuppression, obliterative 
bronchitis, Aspergillus colonization, 
acquired hypogammaglobulinemia, 
presence of bronchial stents, 
reperfusion injury, airway ischemia
68
Pancreas (+kidney) 10–40 >90% Candida,
0%–3% Aspergillus
Similar factors to the liver 
and kidney transplant, 
graft lost (vascular graft 
thrombosis, post-reperfusion 
pancreatitis), enteric drainage, 
alemtuzumab-containing 
immunosuppresive regimen
100
Small bowel 30–60 80%–100% Candida, 0%–5% 
Aspergillus
Not clearly determined, similar 
factors to others intraabdominal 
SOT recipients; Graft 
rejection/dysfunction, enhanced 
immunosuppression, anastomotic 
disruption, multi-visceral transplant
66
Abbreviations: SOT, solid organ transplantation/solid organ transplant recipients; IFI, invasive fungal infection; IA, invasive aspergillosis; CMV, cytomegalovirus.Therapeutics and Clinical Risk Management 2008:4(6) 1276
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prevents IA in OLT. A recent meta-analysis of antifungal 
prophylaxis in OLT demonstrated no beneﬁ  cial effect on 
IA. Observational studies, however, suggest that targeted 
prophylaxis with lipid formulations of AmB may be effec-
tive in preventing IA in high-risk OLT recipients (Singh et al 
2001; Fortun et al 2003). Lipid formulations of AmB at a 
dose of 5 mg/kg/day have been shown to be efﬁ  cacious in 
reducing IFI in high-risk OLT recipients on renal replacement 
therapy, although there was no reduction in mortality. A study 
of universal prophylaxis with cumulative doses of 1–1.5 g of 
liposomal or lipid complex AmB showed a reduction in the 
incidence of IA, which was most signiﬁ  cant among patients 
receiving renal replacement therapy (0% vs 32% on controls). 
However, low doses of lipid formulations of AmB failed to 
prevent IA (Tollemar et al 1995).
The efﬁ  cacy of the antifungal prophylaxis oral solution 
of itraconazole as has been assessed in two reports on OLT 
recipients. A randomized, controlled trial of itraconazole 
in an oral solution (200 mg every 12 h) versus intravenous 
or oral ﬂ  uconazole (400 mg every 24 h) documented no 
signiﬁ  cant difference in the incidence of IA (Winston and 
Busuttil 2002).
On the other hand, the Spanish group GESITRA 
has communicated recently the preliminary results of a 
prospective, noncomparative, open label trial on antifungal 
prophylaxis with caspofungin in high-risk OLT recipients 
(Fortun et al 2007). Overall, caspofungin prophylaxis was 
successful in 87.8% of the patients. These results suggest 
promise for the prophylactic use of echinocandins in high 
risk OLT.
However, it is controversial the election of antifungal 
agent for prophylaxis in these patients. The high cost and 
the need of parenteral infusion limits the use of lipid for-
mulations of AmB and caspofungin. Despite in vitro data 
suggesting that caspofungin in combination with calcineurin or 
TOR-inhibitors may have enhanced activity against Aspergil-
lus, breakthrough infections in patients on caspofungin have 
been noted (Kontoyiannis et al 2003). The recommendations 
for prophylaxis against Aspergillus in OLT are a lipid 
formulation of AmB, voriconazole or caspofungin, with a 
duration of 3–4 weeks or until resolution of risk factors. In 
heart transplant recipients routine antifungal prophylaxis is not 
warranted, but in patients deemed to be at high risk (Table 6), 
itraconazole at 400 mg daily administered orally from day 5 
after transplantation for 3 to 6 months is associated with a 
signiﬁ  cantly lower incidence of IA (Munoz et al 2004).
Randomized studies in high-risk patients are needed to 
determine the efﬁ  cacy of targeted antifungal prophylaxis 
for the prevention of IA. In the meantime, each centre needs 
to evaluate its own recipient risk factors and rates of IA to 
determine whether these strategies are appropriate for its 
patients (Biancoﬁ  ore et al 2002).
In conclusion, targeted prophylaxis against Candida and 
Aspergillus spp. is recommended in all SOT. Fluconazole 
should be used for prophylaxis against Candida spp. unless 
the institution has a high rate of non-albicans infections; 
conversely, voriconazole is recomended for prophylaxis 
against Aspergillus spp. allthough its signiﬁ  cant interactions 
with immunosuppressive agents could be a potential limiting 
factor.
Targeted therapy of IFI in solid organ 
transplant patients
With regard to the treatment, voriconazole, an extended 
spectrum highly lipophilic triazole with 98% oral bioavail-
ability, is actually the ﬁ  rst choice for initial therapy of IA 
in LT patients and other immunosuppressed hosts. Further-
more, the ﬁ  rst experiences with LT patients also evidenced 
that continuous infusion of AmB is well tolerated, safe and 
efﬁ  cient (Speich et al 2002). Other potentially effective thera-
pies include lipid formulations of AmB and echinocandins. 
Combination therapy using a triazole and an echinocandin 
has been evaluated in SOT, with a signiﬁ  cant reduction in 
mortality in those patients with renal failure and infected by 
A. fumigatus (Singh et al 2006a).
In conclusion, IFIs, especially immunocompromised 
and critical care patients, have become an excellent target 
for prophylactic, empiric, and pre-emptive therapy interven-
tions due to high morbidity and mortality rates, an increasing 
incidence, and associated health care costs. Early diagnosis 
and treatment are associated with a better prognosis. In all 
cases the choice of antifungal drug must be based on the 
individual characteristics of the patient. A tailored therapy 
(de-escalation) must also be considered in the ICU setting. 
Furthermore, risk-adapted prophylaxis is the best option in 
hematological and SOT patients.
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